Brooklyn ImmunoTherapeutics Inc. (BTX) News
Filter BTX News Items
BTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BTX News Highlights
- BTX's 30 day story count now stands at 4.
- Over the past 7 days, the trend for BTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BTX are MRNA, IPSC and NA.
Latest BTX News From Around the Web
Below are the latest news stories about BROOKLYN IMMUNOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BTX as an investment opportunity.
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies CongressSAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston. Details of Presentation Title: Avoiding Vector Integration Using mRNA Vectorization of |
Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis BiotherapeuticsThe Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced ‘stealthing’ edits, and can target virtually any cancer antigen SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop |
Brooklyn ImmunoTherapeutic changing name to Eterna Therapeutics on MondayMARKET PULSE Brooklyn ImmunoTherapeutics Inc. (BTX) said Tuesday it’ll change its stock trading ticker to ERNA on Monday, Oct. 17, as part of a name change to Eterna Therapeutics Inc. The San Diego-based clinical stage biopharmaceutical company said the new name reflects its focus on developing advanced therapies using its patented mRNA cell engineering technologies. |
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNew name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Na |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer StudyBrooklyn ImmunoTherapeutics Inc (NASDAQ: BTX) has announced results from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The study's primary endpoint was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. 150 patients were enrolled in the study. At two years of follow-up in the intention-to-treat (n=105) population, the median EFS was 48.3 mon |
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerSAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and |
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencySAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per sha |
Brooklyn ImmunoTherapeutics Announces Board ChangesSAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim Chief Executive Officer (“CEO”) of Brooklyn and Co-Founder, |
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingSAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will |